Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | GLS | O94925 | 9/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | PANK3 | Q9H999 | 4/20 | 0.40 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31717786 | 0.89 | PANK3 (0.52) | RPS6KB1PANK3 | |
| SCHEMBL21406381 | 0.89 | PANK3 (0.52) | RPS6KB1PANK3 | |
| SCHEMBL21406384 | 0.89 | PANK3 (0.52) | RPS6KB1PANK3 | |
| SCHEMBL26501564 | 0.88 | SIGMAR1 (0.44) | SIGMAR1GLSMCHR1PANK3 | |
| SCHEMBL26501535 | 0.84 | PANK3 (0.52) | SIGMAR1GLSPANK3 | |
| SCHEMBL26501563 | 0.81 | GLS (0.41) | SIGMAR1GLSPANK3 | |
| SCHEMBL26501529 | 0.77 | PANK3 (0.48) | GLSPANK3 | |
| SCHEMBL26501525 | 0.77 | PANK3 (0.48) | GLSPANK3 | |
| SCHEMBL23054437 | 0.75 | PANK3 (0.67) | SIGMAR1PANK3 | |
| SCHEMBL23054435 | 0.75 | PANK3 (0.67) | SIGMAR1PANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | SIGMAR1 3593/4885GLS 57/4885RPS6KB1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.